DDIT3 and diffuse large B-cell lymphoma: Lower RDI generally has been associated with worse outcomes in humans with diffuse large B‐cell lymphoma treated with R‐CHOP (rituximab + CHOP), although this is not a generalized finding, particularly in the ≥80 years of age subpopulation.34